Protective effect of metformin on myocardial injury in metabolic syndrome patients following percutaneous coronary intervention

Cardiology (Switzerland)

Volumn 127, Issue 2, 2014, Pages 133-139

  Li, Jing ^a   Xu, Jin Peng ^a   Zhao, Xing Zhou ^a   Sun, Xue Jiang ^a   Xu, Zhan Wen ^a   Song, Shu Jiang ^a  

^a HEBEI UNIVERSITY   (China)

Author keywords

Metabolic syndrome; Metformin; Myocardial injury; Percutaneous coronary intervention

Indexed keywords

CREATINE KINASE MB; METFORMIN; TROPONIN I; ACETYLSALICYLIC ACID; CLOPIDOGREL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEATH; ELECTIVE SURGERY; FEMALE; HEART INFARCTION; HEART MUSCLE INJURY; HOSPITALIZATION; HUMAN; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OPEN STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; YOUNG ADULT; CARDIOVASCULAR RISK; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; LOADING DRUG DOSE; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; BIOLOGICAL MARKERS; CARDIOTONIC AGENTS; CREATINE KINASE, MB FORM; HUMANS; METABOLIC SYNDROME X; METFORMIN; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; TROPONIN I; YOUNG ADULT;

EID: 84893317231     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000355574     Document Type: Article

References (21)

1. Califf RM, Abdelmeguid AE, Kuntz RE, Popma JJ, Davidson CJ, Cohen EA, Kleiman NS, Mahaffey KW, Topol EJ, Pepine CJ, Lipicky RJ, Granger CB, Harrington RA, Tardiff BE, Crenshaw BS, Bauman RP, Zuckerman BD, Chaitman BR, Bittl JA, Ohman EM: Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998; 31: 241-251.
2. Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG: Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 1996; 94: 1528-1536.
3. Brener SJ, Ellis SG, Schneider J, Topol EJ: Frequency and long-term impact of myonecrosis after coronary stenting. Eur Heart J 2002; 23: 869-876.
4. Ioannidis JP, Karvouni E, Katritis DG: Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous intervention. J Am Coll Cardiol 2003; 42: 1406-1411.
5. Amano T, Matsubara T, Uetani T, Nanki M, Marui N, Kato M, Arai K, Yokoi K, Ando H, Ishii H, Izawa H, Murohara T: Impact of metabolic syndrome on tissue characteristics of angiographically mild to moderate coronary lesions: integrated backscatter intravascular ultrasound study. J Am Coll Cardiol 2007; 49: 1149-1156.
6. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
7. Solskov L, Lofgren B, Kristiansen SB, Jessen N, Pold R, Nielsen TT, Botker HE, Schmitz O, Lund S: Metformin induces cardioprotection against ischaemia/reperfusion injury in the rat heart 24 h after administration. Basic Clin Pharmacol Toxicol 2008; 103: 82-87.
8. Bhamra GS, Hausenloy DJ, Davidson SM, Carr RD, Paiva M, Wynne AM, Mocanu MM, Yellon DM: Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Res Cardiol 2008; 103: 274-284.
9. Paiva M, Riksen NP, Davidson SM, Hausenloy DJ, Monteiro P, Goncalves L, Providencia L, Rongen GA, Smits P, Mocanu MM, Yellon DM: Metformin prevents myocardial reperfusion injury by activating the adenosine receptor. J Cardiovasc Pharmacol 2009; 53: 373- 378.
10. Calvert JW, Gundewar S, Jha S, Greer JJ, Bestermann WH, Tian R, Lefer DJ: Acute metformin therapy confers cardioprotection against myocardial infarction via AMPKeNOS- mediated signaling. Diabetes 2008; 57: 696-705.
11. The IDF Consensus Worldwide Definition of the Metabolic Syndrome. http://www.idf.org/ webdata/docs/IDFMetadeffinal.pdf.
12. Smith SC Jr, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ: Guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines) - executive summary. A report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures (Committee on percutaneous transluminal coronary angioplasty). J Am Coll Cardiol 2001; 37: 2215-2239.
13. Heusch G, Kleinbongard P, Böse D, Levkau B, Haude M, Schulz R, Erbel R: Coronary microembolization from bedside to bench and back to bedside. Circulation 2009; 120: 1822-1836.
14. Amano T, Matsubara T, Uetani T, Nanki M, Marui N, Kato M, Yoshida T, Arai K, Ando H, Kumagai S, Ishii H, Izawa H, Murohara T: Abnormal glucose regulation is associated with lipid-rich coronary plaque: relationship to insulin resistance. JACC Cardiovasc Imaging 2008; 1: 39-45.
15. Boyle JG, Salt IP, McKay GA: Metformin action on AMP-activated protein kinase: a translational research approach to understanding a potential new therapeutic target. Diabet Med 2010; 27: 1097-1106.
16. Zhang L, He H, Balschi JA: Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration. Am J Physiol Heart Circ Physiol 2007; 293:H457-H466.
17. Mubagwa K, Flameng W: Adenosine, adenosine receptors and myocardial protection: an updated overview. Cardiovasc Res 2001; 52: 25-39.
18. Riksen NP, Smits P, Rongen GA: Ischaemic preconditioning: from molecular characterisation to clinical application. Part I. Neth J Med 2004; 62: 353-363.
19. Krysiak R, Okopien B: The effect of metformin on monocyte secretory function in simvastatin- treated patients with impaired fasting glucose. Metabolism 2013; 62: 39-43.
20. Gin H, Freyburger G, Boisseau M, Aubertin J: Study of the effect of metformin on platelet aggregation in insulin-dependent diabetics. Diabetes Res Clin Pract 1989; 6: 61-67.
21. Timmer JR, Ottervanger JP, de Boer MJ, Dambrink JH, Hoorntje JC, Gosselink AT, Suryapranata H, Zijlstra F, van't Hof AW: Hyperglycaemia is an important predictor of impaired coronary flow before reperfusion therapy in ST-segment elevation myocardial infarction. J Am Coll Cardiol 2005; 45: 999- 1002.